Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05952037

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Waldenstrom Macroglobulinemia Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases Waldenstrom's Macroglobulinemia Recurrent Waldenstrom's Macroglobulinemia Refractory

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Concord Repatriation General Hospital, Concord, New South Wales, Australia

Loading trial locations.

About this study

This study will test whether sonrotoclax (BGB-11417) can be used to improve outcomes in participants with Waldenström's Macroglobulinemia (WM) both when used alone in those who have not responded well to conventional treatments and when used in combination with zanubrutinib in those who have not yet received treatment. The main goals of the study are to determine how many participants no longer have evidence of cancer or have some improvement in the signs and symptoms of cancer after treatment, and to determine what adverse events, or side effects, participants might experience.

BCL2 is a key protein involved in cell death, and abnormal levels of BCL2 are associated with many cancers. Blocking the action of BCL2 proteins is a promising approach with potential therapeutic benefits in participants with different types of cancers, including WM. This study will enroll approximately 105 participants. All participants will receive sonrotoclax orally as a tablet.

The study will take place at multiple centers worldwide. The overall time to participate in this study is approximately 5 years.

Note: Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical and definitive histologic diagnosis of WM.
  • Meeting ≥ 1 criterion for treatment according to consensus panel criteria from the 2nd International Workshop on Waldenström's Macroglobulinemia (IWWM).
  • For Cohorts 1-3, refractory or relapsed disease at study entry unless participants had intolerance to the most recent therapy. Refractory disease is defined as not attaining at least a major response, or progressing while on or within 6 months of completing therapy. Relapsed disease is defined as attaining at least a major response to therapy and meeting the criteria for disease progression beyond 6 months after completing therapy.
  • For Cohort 4, patients must not have received prior therapy for WM (except for plasmapheresis).
  • Adequate organ function.

Exclusion criteria

  • Central nervous system (CNS) involvement by WM.
  • Transformation to aggressive lymphoma, such as diffuse large B-cell lymphoma.
  • History of other malignancies ≤ 2 years before study entry.
  • Uncontrolled active systemic infection or recent infection requiring parenteral antimicrobial therapy that was completed ≤ 14 days before the first dose of the study drug.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Treatment and study plan

Sonrotoclax

Drug

Administered orally as a tablet.

Other names: BGB-11417

Zanubrutinib

Drug

Administered orally as a capsule.

Other names: BRUKINSA, BGB-3111

Primary outcomes

  1. Cohort 1: Major Response Rate (MRR)

    Time frame: Up to approximately 4 years

    MRR is defined as the percentage of participants achieving partial response (PR) or better, as assessed by the Independent Review Committee (IRC) per the 11th International Workshop on Waldenström Macroglobulinemia (IWWM-11) WM response criteria.

Secondary outcomes

  1. Cohorts 2 and 3: MRR as assessed by the IRC

    Time frame: Up to approximately 5 years

    MRR is defined as the percentage of participants achieving PR or better.

  2. All Cohorts: MRR as assessed by the Investigator

    Time frame: Up to approximately 5 years

    MRR is defined as the percentage of participants achieving PR or better.

  3. Cohorts 1, 2, and 3: Duration of Major Response (DoMR) as assessed by the IRC

    Time frame: Up to approximately 5 years

    DoMR is defined as the time from first determination of major response until first documentation of progression or death, whichever occurs first.

  4. All Cohorts: DoMR as assessed by the Investigator

    Time frame: Up to approximately 5 years

    DoMR is defined as the time from first determination of major response until first documentation of progression or death, whichever occurs first.

  5. Cohorts 1, 2, and 3: Complete Response (CR) + Very Good Partial Response (VGPR) as assessed by the IRC

    Time frame: Up to approximately 5 years

    CR + VGPR is defined as the percentage of participants who achieve CR or VGPR.

  6. All Cohorts: CR + VGPR as assessed by the Investigator

    Time frame: Up to approximately 5 years

    CR + VGPR is defined as the percentage of participants who achieve CR or VGPR.

  7. Cohorts 1, 2, and 3: Overall Response Rate (ORR) as assessed by the IRC

    Time frame: Up to approximately 5 years

    ORR is defined as the percentage of participants with minor response (MR) or better.

  8. All cohorts: ORR as assessed by the investigator

    Time frame: Up to approximately 5 years

    ORR is defined as the percentage of participants with MR or better.

  9. Cohorts 1, 2, and 3: Duration of Response (DOR) as assessed by the IRC

    Time frame: Up to approximately 5 years

    DOR is defined as the time from first determination of response until first documentation of progression or death, whichever occurs first.

  10. All Cohorts: DOR as assessed by the investigator

    Time frame: Up to approximately 5 years

    DOR is defined as the time from first determination of response until first documentation of progression or death, whichever occurs first.

  11. Cohorts 1, 2, and 3: Progression-Free Survival (PFS)

    Time frame: Up to approximately 5 years

    PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the IRC and by the investigator.

  12. Cohorts 1, 2, and 3: Time to major response as assessed by the IRC

    Time frame: Up to approximately 5 years

    Time to major response is defined as the time from start of study treatment to the first documentation of major response.

  13. All Cohorts: Time to major response as assessed by the investigator

    Time frame: Up to approximately 5 years

    Time to major response is defined as the time from start of study treatment to the first documentation of major response.

  14. Cohorts 1, 2, and 3: Overall Survival (OS)

    Time frame: Up to approximately 5 years

    OS is defined as the time from first study drug administration to the date of death due to any cause.

  15. Cohort 4: Time to next treatment

    Time frame: Up to approximately 5 years

    Defined as the time from the start of treatment to the start of first subsequent therapy for WM.

  16. Number of participants reporting adverse events

    Time frame: Up to approximately 5 years

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory abnormalities, physical examination results, and vital signs.

  17. All Cohorts: Change from Baseline in Health-Related Quality of Life (HRQoL): NFLymSI-18 Disease-related Symptoms-Physical and Treatment-Related Side Effects Subscales

    Time frame: Baseline and approximately months 7, 13, 19, and 25

    HRQoL based on participant-reported outcomes using National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index - 18 Item (NFLymSI-18) Version 4. The questionnaire contains 18 items, each of which utilizes a Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and is divided into a total score.

Sponsors and collaborators

Lead sponsor

BeOne Medicines

Industry

Registry information

Official study title

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia

Important dates

Study start
2023
Primary completion
2026
Study completion
2028
First posted
Jul 19, 2023
Registry last updated
Jan 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.